MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

BACKGROUND: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been comprehensively assessed. METHODS: We perfo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Dagogo-Jack, Ibiayi, Yoda, Satoshi, Lennerz, Jochen K., Langenbucher, Adam, Lin, Jessica J., Rooney, Marguerite, Prutisto-Chang, Kylie, Oh, Audris, Adams, Nathaniel A., Yeap, Beow Y., Chin, Emily, Do, Andrew, Marble, Hetal D., Stevens, Sara E., Digumarthy, Subba R., Saxena, Ashish, Nagy, Rebecca J., Benes, Cyril H., Azzoli, Christopher G., Lawrence, Michael, Gainor, Justin F., Shaw, Alice T., Hata, Aaron N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269872/
https://ncbi.nlm.nih.gov/pubmed/32086345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3906
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller